Table 5 Scenario analyses: incremental costs, QALYs^DW gained and ICERs for the CCC intervention compared to business-as-usual (percentage difference to expected value analysis in parentheses)

Expected value analysis^a

$2,250

0.111

$20,200

Varying phases of CCC intervention

a. CCC from diagnosis to surgery only

$80 (−96 %)

0.009 (−92 %)

$9,100 (−55 %)

b. CCC from surgery to chemotherapy only

$2,170 (−4 %)

0.104 (−6 %)

$20,900 (3 %)

Variations to discount rate

c. 0 % per annum discount rate

$2,520 (12 %)

0.148 (33 %)

$17,100 (−15 %)

d. 6 % per annum discount rate

$2,080 (−8 %)

0.088 (−21 %)

$23,600 (17 %)

Variation to epidemiological parameters

e. Set all DWs (incl pYLDs) to zero (= ‘life years’ gained)

$2,250 (0 %)

0.150 (35 %)

$15,000 (−26 %)

f. Exclude improved quality of life impact of CCC

$2,250 (0 %)

0.100 (−10 %)

$22,400 (11 %)

g. Exclude improved survival due to quicker to surgery

$2,240 (0 %)

0.107 (−4 %)

$21,000 (4 %)

h. Exclude improved survival due to quicker to chemotherapy

$2,130 (−5 %)

0.084 (−24 %)

$25,200 (25 %)

i. Exclude increasing % of patients getting chemotherapy

$800 (−64 %)

0.061 (−45 %)

$13,000 (−36 %)

j. Exclude oxaliplatin

$2,020 (−10 %)

0.095 (−14 %)

$21,300 (5 %)

Variation to cost parameters

k. Scale all health system costs up 20 %

$2330 (4 %)

0.111 (0 %)

$20900 (3 %)

l. Scale all health system costs down 20 %

$2170 (−4 %)

0.111 (0 %)

$19500 (−3 %)

m. Exclude dietician and social worker intervention costs

$1730 (−23 %)

0.111 (0 %)

$15600 (−23 %)

n. Exclude unrelated health system costs (i.e. include costs up to cure time only)

$1780 (−21 %)

0.111 (0 %)

$16000 (−21 %)